Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Kaiser, MF"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-13 z 13
    Tytuł:
    Exploiting gene dependency to inform drug development for multiple myeloma.
    Autorzy:
    Went M; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK. .
    Hoang PH; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
    Law PJ; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
    Kaiser MF; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
    Houlston RS; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
    Pokaż więcej
    Źródło:
    Scientific reports [Sci Rep] 2022 Jul 26; Vol. 12 (1), pp. 12696. Date of Electronic Publication: 2022 Jul 26.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Agents*/pharmacology
    Antineoplastic Agents*/therapeutic use
    Multiple Myeloma*/drug therapy
    Multiple Myeloma*/genetics
    Multiple Myeloma*/pathology
    Drug Development ; Humans
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
    Autorzy:
    Jackson GH; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom.
    Pawlyn C; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.
    Cairns DA; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
    de Tute RM; Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, United Kingdom.
    Hockaday A; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
    Collett C; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
    Jones JR; Kings College Hospital NHS Foundation Trust, London, United Kingdom.
    Kishore B; University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
    Garg M; Leicester Royal Infirmary, Leicester, United Kingdom.
    Williams CD; Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom.
    Karunanithi K; University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom.
    Lindsay J; East Kent Hospitals University NHS Foundation Trust, Canterbury, United Kingdom.
    Rocci A; Manchester University NHS Foundation Trust, Manchester, United Kingdom.; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
    Snowden JA; Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
    Jenner MW; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
    Cook G; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.; Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom.
    Russell NH; Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom.
    Drayson MT; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
    Gregory WM; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
    Kaiser MF; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.
    Owen RG; Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, United Kingdom.
    Davies FE; Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States of America.
    Morgan GJ; Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States of America.
    Pokaż więcej
    Corporate Authors:
    UK NCRI Haemato-oncology Clinical Studies Group
    Źródło:
    PLoS medicine [PLoS Med] 2021 Jan 11; Vol. 18 (1), pp. e1003454. Date of Electronic Publication: 2021 Jan 11 (Print Publication: 2021).
    Typ publikacji:
    Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Multiple Myeloma/*drug therapy
    Adult ; Aged ; Cyclophosphamide/therapeutic use ; Dexamethasone/therapeutic use ; Female ; Humans ; Lenalidomide/therapeutic use ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Oligopeptides/therapeutic use ; Survival Analysis ; United Kingdom
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.
    Autorzy:
    Hinsley S; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
    Walker K; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. .
    Sherratt D; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
    Bailey L; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
    Reed S; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
    Flanagan L; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
    McKee S; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
    Brudenell Straw F; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
    Dawkins B; Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
    Meads D; Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
    Auner HW; Centre for Haematology, Imperial College London, London, UK.
    Kaiser MF; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
    Cook M; Centre for Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
    Brown S; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
    Cook G; Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
    Pokaż więcej
    Corporate Authors:
    Myeloma UK Clinical Trials Network
    Źródło:
    Trials [Trials] 2020 Oct 02; Vol. 21 (1), pp. 826. Date of Electronic Publication: 2020 Oct 02.
    Typ publikacji:
    Clinical Trial Protocol; Journal Article
    MeSH Terms:
    Multiple Myeloma*/drug therapy
    Thalidomide*/adverse effects
    Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Boron Compounds ; Clinical Trials, Phase II as Topic ; Cyclophosphamide/adverse effects ; Dexamethasone/adverse effects ; Glycine/analogs & derivatives ; Humans ; Lenalidomide/adverse effects ; Multicenter Studies as Topic ; Proteasome Inhibitors/adverse effects ; Randomized Controlled Trials as Topic
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    An analysis of the false negative rate of minimal residual disease measurement by multiparameter flow cytometry in multiple myeloma.
    Autorzy:
    Austin M; Haemato-Oncology Department, The Royal Marsden Hospital, Sutton, UK.
    O'Connor S; Histopathology Department, The Royal Marsden Hospital, Sutton, UK.
    Morilla R; Immunophenotyping Laboratory, The Royal Marsden Hospital, Sutton, UK.
    Pawlyn C; Haemato-Oncology Department, The Royal Marsden Hospital, Sutton, UK.; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, UK.
    Kaiser MF; Haemato-Oncology Department, The Royal Marsden Hospital, Sutton, UK.; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, UK.
    Boyd KD; Haemato-Oncology Department, The Royal Marsden Hospital, Sutton, UK.; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, UK.
    Pokaż więcej
    Źródło:
    International journal of laboratory hematology [Int J Lab Hematol] 2020 Apr; Vol. 42 (2), pp. e65-e67. Date of Electronic Publication: 2019 Sep 20.
    Typ publikacji:
    Letter
    MeSH Terms:
    Flow Cytometry/*methods
    Multiple Myeloma/*diagnosis
    Neoplasm, Residual/*diagnosis
    Plasma Cells/*metabolism
    False Negative Reactions ; Humans ; Immunohistochemistry/methods ; Multiple Myeloma/metabolism ; Sensitivity and Specificity
    Opinia redakcyjna
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report.
    Autorzy:
    Shah V; Division of Molecular Pathology, The Institute of Cancer Research, London, UK. .
    Boyd KD; Department of Haemato-Oncology, Royal Marsden Hospital, London, UK.
    Houlston RS; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
    Kaiser MF; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
    Pokaż więcej
    Źródło:
    BMC cancer [BMC Cancer] 2017 Nov 06; Vol. 17 (1), pp. 718. Date of Electronic Publication: 2017 Nov 06.
    Typ publikacji:
    Case Reports; Journal Article
    MeSH Terms:
    Germ-Line Mutation*
    Cyclin-Dependent Kinase Inhibitor p18/*genetics
    Multiple Myeloma/*therapy
    Adult ; Cyclin-Dependent Kinase Inhibitor p16 ; Female ; Humans ; Melphalan/therapeutic use ; Multiple Myeloma/genetics ; Pedigree ; Stem Cell Transplantation ; Survivorship ; Transplantation, Autologous
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.
    Autorzy:
    Sriskandarajah P; a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.; b The Institute of Cancer Research , London , UK.
    Pawlyn C; a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.; b The Institute of Cancer Research , London , UK.
    Mohammed K; a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.
    Dearden CE; a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.
    Davies FE; a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.; c Myeloma Institute, University of Arkansas for Medical Sciences , Little Rock , AR , USA.
    Morgan GJ; a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.; c Myeloma Institute, University of Arkansas for Medical Sciences , Little Rock , AR , USA.
    Boyd KD; a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.
    Kaiser MF; a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.; b The Institute of Cancer Research , London , UK.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2017 Feb; Vol. 58 (2), pp. 494-497. Date of Electronic Publication: 2016 Jul 20.
    Typ publikacji:
    Letter
    MeSH Terms:
    Angiogenesis Inhibitors/*therapeutic use
    Antineoplastic Agents/*therapeutic use
    Multiple Myeloma/*drug therapy
    Thalidomide/*analogs & derivatives
    Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Combined Modality Therapy ; Drug Resistance, Neoplasm ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Multiple Myeloma/diagnosis ; Multiple Myeloma/mortality ; Neoplasm Grading ; Neoplasm Staging ; Recurrence ; Retreatment ; Thalidomide/administration & dosage ; Thalidomide/adverse effects ; Thalidomide/therapeutic use ; Treatment Outcome
    Opinia redakcyjna
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma.
    Autorzy:
    Melchor L; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
    Brioli A; 1] Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, UK [2] Istituto di Ematologia Seràgnoli, Università degli Studi di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
    Wardell CP; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
    Murison A; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
    Potter NE; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
    Kaiser MF; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
    Fryer RA; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
    Johnson DC; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
    Begum DB; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
    Hulkki Wilson S; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
    Vijayaraghavan G; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
    Titley I; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
    Cavo M; Istituto di Ematologia Seràgnoli, Università degli Studi di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
    Davies FE; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
    Walker BA; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
    Morgan GJ; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
    Pokaż więcej
    Źródło:
    Leukemia [Leukemia] 2014 Aug; Vol. 28 (8), pp. 1705-15. Date of Electronic Publication: 2014 Jan 13.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Clonal Evolution*
    Phylogeny*
    Single-Cell Analysis*
    Multiple Myeloma/*genetics
    Aged ; Animals ; Chromosomes, Human, Pair 11 ; Chromosomes, Human, Pair 14 ; Female ; Genes, ras ; Humans ; Interferon Regulatory Factors/genetics ; Male ; Mice ; Mice, SCID ; Middle Aged ; Mutation ; Selection, Genetic ; Translocation, Genetic
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    A novel functional role for MMSET in RNA processing based on the link between the REIIBP isoform and its interaction with the SMN complex.
    Autorzy:
    Mirabella F; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, Sutton, United Kingdom.
    Murison A; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, Sutton, United Kingdom.
    Aronson LI; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, Sutton, United Kingdom.
    Wardell CP; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, Sutton, United Kingdom.
    Thompson AJ; Proteomics Core Facility, The Institute of Cancer Research, London, United Kingdom.
    Hanrahan SJ; Proteomics Core Facility, The Institute of Cancer Research, London, United Kingdom.
    Fok JH; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, Sutton, United Kingdom.
    Pawlyn C; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, Sutton, United Kingdom.
    Kaiser MF; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, Sutton, United Kingdom.
    Walker BA; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, Sutton, United Kingdom.
    Davies FE; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, Sutton, United Kingdom.
    Morgan GJ; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, Sutton, United Kingdom.
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2014 Jun 12; Vol. 9 (6), pp. e99493. Date of Electronic Publication: 2014 Jun 12 (Print Publication: 2014).
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    RNA Processing, Post-Transcriptional*
    Histone-Lysine N-Methyltransferase/*metabolism
    Repressor Proteins/*metabolism
    SMN Complex Proteins/*metabolism
    Cell Proliferation ; Chromosomes, Human, Pair 14/genetics ; Chromosomes, Human, Pair 4/genetics ; HeLa Cells ; Histones/metabolism ; Humans ; Introns/genetics ; Mass Spectrometry ; Methylation ; Multiple Myeloma/genetics ; Multiple Myeloma/pathology ; Phenotype ; Protein Binding ; Protein Isoforms/metabolism ; Protein Structure, Tertiary ; RNA Splicing/genetics ; Ribonucleoproteins, Small Nuclear/metabolism ; Spliceosomes/metabolism ; Translocation, Genetic
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.
    Autorzy:
    Walker BA; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.
    Wardell CP; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.
    Melchor L; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.
    Brioli A; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.; Istituto di Ematologia Seràgnoli, Università degli Studi di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
    Johnson DC; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.
    Kaiser MF; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.
    Mirabella F; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.
    Lopez-Corral L; Department of Hematology of the University Hospital of Salamanca; Centro de Investigacion del Cancer (CIC) de Salamanca; and Instituto Biosanitario de Salamanca (IBSAL); Salamanca, Spain.
    Humphray S; Illumina Cambridge Ltd., Chesterford Research Park, Little Chesterford, Saffron Walden, UK.
    Murray L; Illumina Cambridge Ltd., Chesterford Research Park, Little Chesterford, Saffron Walden, UK.
    Ross M; Illumina Cambridge Ltd., Chesterford Research Park, Little Chesterford, Saffron Walden, UK.
    Bentley D; Illumina Cambridge Ltd., Chesterford Research Park, Little Chesterford, Saffron Walden, UK.
    Gutiérrez NC; Department of Hematology of the University Hospital of Salamanca; Centro de Investigacion del Cancer (CIC) de Salamanca; and Instituto Biosanitario de Salamanca (IBSAL); Salamanca, Spain.
    Garcia-Sanz R; Department of Hematology of the University Hospital of Salamanca; Centro de Investigacion del Cancer (CIC) de Salamanca; and Instituto Biosanitario de Salamanca (IBSAL); Salamanca, Spain.
    San Miguel J; Department of Hematology of the University Hospital of Salamanca; Centro de Investigacion del Cancer (CIC) de Salamanca; and Instituto Biosanitario de Salamanca (IBSAL); Salamanca, Spain.
    Davies FE; Targeted Myeloma Treatment, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.
    Gonzalez D; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.
    Morgan GJ; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.
    Pokaż więcej
    Źródło:
    Leukemia [Leukemia] 2014 Feb; Vol. 28 (2), pp. 384-390. Date of Electronic Publication: 2013 Jul 02.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Cell Transformation, Neoplastic/*genetics
    Multiple Myeloma/*genetics
    Cell Transformation, Neoplastic/metabolism ; Disease Progression ; Humans ; Monoclonal Gammopathy of Undetermined Significance/genetics ; Monoclonal Gammopathy of Undetermined Significance/metabolism ; Multiple Myeloma/diagnosis ; Multiple Myeloma/metabolism ; Mutation ; Translocation, Genetic
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma.
    Autorzy:
    Brioli A; Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
    Kaiser MF
    Pawlyn C
    Wu P
    Gregory WM
    Owen R
    Ross FM
    Jackson GH
    Cavo M
    Davies FE
    Morgan GJ
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2013 Sep; Vol. 54 (9), pp. 1975-81. Date of Electronic Publication: 2013 Jan 23.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Immunosuppressive Agents/*therapeutic use
    Multiple Myeloma/*drug therapy
    Thalidomide/*therapeutic use
    Aged ; Female ; Humans ; In Situ Hybridization, Fluorescence ; Maintenance Chemotherapy ; Male ; Middle Aged ; Multiple Myeloma/diagnosis ; Multiple Myeloma/mortality ; Neoplasm Staging ; Translocation, Genetic ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR.
    Autorzy:
    Kaiser MF
    Walker BA
    Hockley SL
    Begum DB
    Wardell CP
    Gonzalez D
    Ross FM
    Davies FE
    Morgan GJ
    Pokaż więcej
    Źródło:
    Leukemia [Leukemia] 2013 Aug; Vol. 27 (8), pp. 1754-7. Date of Electronic Publication: 2013 Jan 15.
    Typ publikacji:
    Letter; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Multiple Myeloma/*diagnosis
    Multiple Myeloma/*genetics
    Gene Expression Regulation, Neoplastic ; Humans ; Immunoglobulin Heavy Chains/genetics ; Multiple Myeloma/mortality ; Prognosis ; Real-Time Polymerase Chain Reaction ; Translocation, Genetic
    Raport
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.
    Autorzy:
    Weinhold N; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
    Johnson DC; Haemato-Oncology Research Unit, Division of Molecular Pathology, Institute of Cancer Research, Surrey, UK.
    Chubb D; Division of Genetics and Epidemiology, Institute of Cancer Research, Surrey, UK.
    Chen B; German Cancer Research Center, Heidelberg, Germany.
    Försti A; German Cancer Research Center, Heidelberg, Germany.; Center for Primary Health Care Research, Lund University, Malmo, Sweden.
    Hosking FJ; Division of Genetics and Epidemiology, Institute of Cancer Research, Surrey, UK.
    Broderick P; Division of Genetics and Epidemiology, Institute of Cancer Research, Surrey, UK.
    Ma YP; Division of Genetics and Epidemiology, Institute of Cancer Research, Surrey, UK.
    Dobbins SE; Division of Genetics and Epidemiology, Institute of Cancer Research, Surrey, UK.
    Hose D; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.; National Centre for Tumour Diseases, Heidelberg, Germany.
    Walker BA; Haemato-Oncology Research Unit, Division of Molecular Pathology, Institute of Cancer Research, Surrey, UK.
    Davies FE; Haemato-Oncology Research Unit, Division of Molecular Pathology, Institute of Cancer Research, Surrey, UK.
    Kaiser MF; Haemato-Oncology Research Unit, Division of Molecular Pathology, Institute of Cancer Research, Surrey, UK.
    Li NL; Haemato-Oncology Research Unit, Division of Molecular Pathology, Institute of Cancer Research, Surrey, UK.
    Gregory WA; University of Leeds, Leeds, UK.
    Jackson GH; Royal Victoria Infirmary, Newcastle-on-Tyne, UK.
    Witzens-Harig M; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
    Neben K; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
    Hoffmann P; Institute of Human Genetics, University of Bonn, Germany.
    Nöthen MM; Institute of Human Genetics, University of Bonn, Germany.; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
    Mühleisen TW; Institute of Human Genetics, University of Bonn, Germany.
    Eisele L; Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
    Ross FM; Cytogenetics Group, Wessex Regional Cytogenetic Laboratory, Salisbury, UK.
    Jauch A; Institute of Human Genetics, University of Heidelberg, Germany.
    Goldschmidt H; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.; National Centre for Tumour Diseases, Heidelberg, Germany.
    Houlston RS; Division of Genetics and Epidemiology, Institute of Cancer Research, Surrey, UK.
    Morgan GJ; Haemato-Oncology Research Unit, Division of Molecular Pathology, Institute of Cancer Research, Surrey, UK.
    Hemminki K; German Cancer Research Center, Heidelberg, Germany.; Center for Primary Health Care Research, Lund University, Malmo, Sweden.
    Pokaż więcej
    Źródło:
    Nature genetics [Nat Genet] 2013 May; Vol. 45 (5), pp. 522-525. Date of Electronic Publication: 2013 Mar 17.
    Typ publikacji:
    Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Genome-Wide Association Study*
    Translocation, Genetic*
    Chromosomes, Human, Pair 11/*genetics
    Chromosomes, Human, Pair 14/*genetics
    Cyclin D1/*genetics
    Multiple Myeloma/*etiology
    Polymorphism, Single Nucleotide/*genetics
    Case-Control Studies ; Genome, Human ; Genotype ; Humans ; In Situ Hybridization, Fluorescence ; Karyotyping ; Phenotype ; Risk Factors
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.
    Autorzy:
    Kaiser MF; Department of Haematology and Oncology, Charité Universitätsmedizin Berlin, Berlin, Germany.
    Heider U
    Mieth M
    Zang C
    von Metzler I
    Sezer O
    Pokaż więcej
    Źródło:
    European journal of haematology [Eur J Haematol] 2013 Apr; Vol. 90 (4), pp. 263-72. Date of Electronic Publication: 2013 Feb 15.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Boronic Acids/*pharmacology
    Osteoblasts/*cytology
    Osteoblasts/*drug effects
    Proteasome Inhibitors/*pharmacology
    Pyrazines/*pharmacology
    Receptors, Calcitriol/*metabolism
    Base Sequence ; Bortezomib ; Cell Differentiation/drug effects ; Cell Differentiation/physiology ; Cell Line, Tumor ; Cells, Cultured ; Coculture Techniques ; Humans ; Mesenchymal Stem Cells/cytology ; Mesenchymal Stem Cells/drug effects ; Mesenchymal Stem Cells/metabolism ; Multiple Myeloma/complications ; Multiple Myeloma/drug therapy ; Multiple Myeloma/metabolism ; Osteoblasts/metabolism ; Osteocalcin/genetics ; Osteoclasts/cytology ; Osteoclasts/drug effects ; Osteoclasts/metabolism ; Osteopontin/genetics ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Receptors, Calcitriol/genetics ; Recombinant Proteins/genetics ; Recombinant Proteins/metabolism ; Signal Transduction/drug effects ; Transfection ; Up-Regulation/drug effects ; Vitamin D Deficiency/drug therapy ; Vitamin D Deficiency/etiology ; Vitamin D Deficiency/metabolism
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
      Wyświetlanie 1-13 z 13

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies